PMCC PMCC

Search tips
Search criteria

Advanced
Results 1-3 (3)
 

Clipboard (0)
None

Select a Filter Below

Journals
Authors
more »
Year of Publication
Document Types
author:("holly, Gábor")
1.  Fixed-Dose Combination of Tafluprost and Timolol in the Treatment of Open-Angle Glaucoma and Ocular Hypertension: Comparison with Other Fixed-Combination Products 
Advances in Therapy  2014;31(9):932-944.
A new preservative-free fixed-dose combination of 0.0015% tafluprost, a prostaglandin F2α analog, and 0.5% timolol (TAF/TIM; Santen Oy, Tampere, Finland), a beta-adrenergic antagonist has recently been developed. The intraocular pressure (IOP) reduction with TAF/TIM in open-angle glaucoma and ocular hypertension is similar to that of other prostaglandin–timolol fixed-combination products. Patients with high IOP responded well to TAF/TIM with reductions of up to 40% (>13 mmHg) and beyond. Compared to previous controlled and double-masked clinical trials with DuoTrav® (Alcon, Fort Worth, USA) and Ganfort® (Allergan, Irvine, USA), TAF/TIM caused less superficial ocular side effects and less conjunctival hyperemia. Plausible explanations for the differences in side effects between the fixed-combination products are discussed.
Electronic supplementary material
The online version of this article (doi:10.1007/s12325-014-0151-7) contains supplementary material, which is available to authorized users.
doi:10.1007/s12325-014-0151-7
PMCID: PMC4177040  PMID: 25213118
DuoTrav®; Fixed-dose combination; Ganfort®; Hyperemia; Intraocular pressure; Ophthalmology; Preservative free; Side effects; Tafluprost; Timolol; Xalacom®
2.  The manoeuvrability hypothesis to explain the maintenance of bilateral symmetry in animal evolution 
Biology Direct  2012;7:22.
Background
The overwhelming majority of animal species exhibit bilateral symmetry. However, the precise evolutionary importance of bilateral symmetry is unknown, although elements of the understanding of the phenomenon have been present within the scientific community for decades.
Presentation of the hypothesis
Here we show, with very simple physical laws, that locomotion in three-dimensional macro-world space is itself sufficient to explain the maintenance of bilateral symmetry in animal evolution. The ability to change direction, a key element of locomotion, requires the generation of instantaneous “pushing” surfaces, from which the animal can obtain the necessary force to depart in the new direction. We show that bilateral is the only type of symmetry that can maximize this force; thus, an actively locomoting bilateral body can have the maximal manoeuvrability as compared to other symmetry types. This confers an obvious selective advantage on the bilateral animal.
Implications of the hypothesis
These considerations imply the view that animal evolution is a highly channelled process, in which bilateral and radial body symmetries seem to be inevitable.
Reviewers
This article was reviewed by Gáspár Jékely, L. Aravind and Eugene Koonin.
doi:10.1186/1745-6150-7-22
PMCID: PMC3438024  PMID: 22789130
Bilateral symmetry; Radial symmetry; Manoeuvrability; Drag; Drag coefficient
3.  Efficacy and safety of travoprost/timolol vs dorzolamide/timolol in patients with open-angle glaucoma or ocular hypertension 
Purpose:
To compare the intraocular pressure- (IOP-) lowering efficacy of fixed combinations travoprost 0.004%/timolol 0.5% and dorzolamide 2%/timolol 0.5% in patients with ocular hypertension or open-angle glaucoma.
Methods:
In this prospective, multicenter, double-masked, randomized clinical trial, 319 qualifying patients received either travoprost/timolol once daily in the morning (n = 157) or dorzolamide/timolol twice daily (n = 162). IOP was assessed morning and evening at 2 and 6 weeks. The primary outcome measure was mean diurnal IOP.
Results:
Baseline mean IOP values were similar between groups. Mean pooled diurnal IOP was significantly lower in the travoprost/timolol group (16.5 mmHg ± 0.23) than in the dorzolamide/timolol group (17.3 mmHg ± 0.23; P = 0.011). Mean IOP was significantly lower in the travoprost/timolol group compared to the dorzolamide/timolol group at the 9 AM time point both at Week 2 (P = 0.006) and Week 6 (P = 0.002). The travoprost/timolol combination produced mean IOP reductions from baseline of 35.3% to 38.5%, while the dorzolamide/timolol combination produced mean IOP reductions from baseline of 32.5% to 34.5%.
Conclusions:
The fixed combination travoprost 0.004%/timolol 0.5% dosed once daily in the morning demonstrated superior mean diurnal IOP-lowering efficacy compared to dorzolamide 2%/timolol 0.5% dosed twice daily in patients with ocular hypertension or open-angle glaucoma.
PMCID: PMC2788589  PMID: 19997566
dorzolamide; fixed combination; glaucoma; IOP-lowering therapy; timolol; travoprost

Results 1-3 (3)